Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06418724 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma

Study acronym: NEOPECS
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 years later Jul 30, 2026 → Jul 30, 2030
See other at-risk trials from Melanoma and Skin Cancer Trials Limited

Record History

  1. Primary completion pushed from Jul 30, 2026 to Jul 30, 2030 Start date: Jul 30, 2026 to Oct 30, 2026 · Secondary endpoints: details revised at 7 of 8 entries · Eligibility criteria shortened, about 2 words Show 3 more changesShow less
    • Start date: Jul 30, 2026 to Oct 30, 2026
    • Secondary endpoints: details revised at 7 of 8 entries
    • Eligibility criteria shortened, about 2 words
  2. Primary completion date: Jan 1, 2026 to Jul 30, 2026 Start date: Dec 11, 2025 to Jul 30, 2026 · Completion date: Dec 1, 2028 to Dec 1, 2030v4 Show 2 more changesShow less
    • Start date: Dec 11, 2025 to Jul 30, 2026
    • Completion date: Dec 1, 2028 to Dec 1, 2030
  3. Start date: Dec 11, 2024 to Dec 11, 2025v3
  4. Start date: Aug 1, 2024 to Dec 11, 2024 Completion date: Nov 1, 2027 to Dec 1, 2028v2 Show 1 more changeShow less
    • Completion date: Nov 1, 2027 to Dec 1, 2028
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The NEOPECS trial is a phase II prospective, single-arm, non-randomised interventional trial for patients with borderline resectable locally advanced cutaneous squamous cell carcinoma with a 6-participant safety lead in to ensure safety of the combination in the neoadjuvant setting across 3 sites in Australia.
Trial Details
NCT Number NCT06418724
Lead Sponsor Melanoma and Skin Cancer Trials Limited
Conditions Locally Advanced Cutaneous Squamous Cell Carcinoma
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov